ReviewFrontiers in cardiovascular medicine2025
MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advances.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- Single particle mediated CRISPR/Cas13a ultrasensitive direct detection of miRNA-21 at femtomolar levels without nucleic acid amplification.Mikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anthracycline-based chemotherapy is a highly effective treatment for numerous cancers, yet its clinical use is severely limited by cumulative, dose-dependent cardiotoxicity. MicroRNAs (miRNAs), as key post-transcriptional regulators of gene expression, play a pivotal role in the pathophysiology of cardiovascular disease, but their specific functions in anthracycline-induced cardiotoxicity (AIC) require systematic elucidation. Purpose: This review aims to systematically summarize current research on the key miRNAs, their molecular targets, and associated signaling pathways that regulate AIC, while also exploring their potential as biomarkers for early diagnosis and as therapeutic targets for intervention. Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus databases for relevant studies published up to April 2025. Search terms included combinations of "microRNA," "anthracycline," "doxorubicin," "cardiotoxicity," and "cardiomyopathy." Results: A complex network of miRNAs is involved in the regulation of AIC. Pro-toxic miRNAs, such as miR-34a and miR-146a, exacerbate cardiomyocyte apoptosis and oxidative stress by targeting Sirtuin 1 (SIRT1) and anti-apoptotic proteins. In contrast, cardioprotective miRNAs, such as miR-21 and miR-133a, mitigate cardiac injury by inhibiting fibrosis and apoptosis pathways. This network dynamically influences the onset and progression of AIC, affecting key processes including oxidative stress, autophagy, fibrosis, and apoptosis. Conclusion: MiRNAs play a dual role in the pathomechanisms of AIC, acting as both pathogenic factors and protective agents. A deeper understanding of this regulatory network provides a solid theoretical foundation for developing novel miRNA-based diagnostic biomarkers and intervention strategies to manage AIC. Future research should focus on validating clinical biomarker panels and optimizing targeted delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.